首页> 美国卫生研究院文献>Pharmaceuticals >Repurposing Clinical Agents for Chemical Exchange Saturation Transfer Magnetic Resonance Imaging: Current Status and Future Perspectives
【2h】

Repurposing Clinical Agents for Chemical Exchange Saturation Transfer Magnetic Resonance Imaging: Current Status and Future Perspectives

机译:修复化学交换饱和转移磁共振成像的临床试剂:当前状态和未来的观点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Molecular imaging is becoming an indispensable tool to pursue precision medicine. However, quickly translating newly developed magnetic resonance imaging (MRI) agents into clinical use remains a formidable challenge. Recently, Chemical Exchange Saturation Transfer (CEST) MRI is emerging as an attractive approach with the capability of directly using low concentration, exchangeable protons-containing agents for generating quantitative MRI contrast. The ability to utilize diamagnetic compounds has been extensively exploited to detect many clinical compounds, such as FDA approved drugs, X-ray/CT contrast agents, nutrients, supplements, and biopolymers. The ability to directly off-label use clinical compounds permits CEST MRI to be rapidly translated to clinical settings. In this review, the current status of CEST MRI based on clinically available compounds will be briefly introduced. The advancements and limitations of these studies are reviewed in the context of their pre-clinical or clinical applications. Finally, future directions will be briefly discussed.
机译:分子成像正成为追求精密药物的不可或缺的工具。然而,将新开发的磁共振成像(MRI)药剂迅速转化为临床用途仍然是一个强大的挑战。最近,化学交换饱和度转移(CEST)MRI作为一种有吸引力的方法,其具有直接使用低浓度,可含有可更换的含质子剂的能力,用于产生定量MRI对比度。利用抗磁化合物的能力已经广泛利用以检测许多临床化合物,例如FDA批准的药物,X射线/ CT造影剂,营养,补充剂和生物聚合物。直接脱离标签使用临床化合物的能力允许CEST MRI迅速翻译成临床环境。在本综述中,将简要介绍基于临床可用化合物的CEST MRI的当前状态。在临床前或临床应用的背景下审查了这些研究的进步和局限性。最后,将简要讨论未来的方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号